Aitia’s Gemini Digital Twin (GDT) platform merges our proprietary causal AI and simulation reverse-engineering and forward-simulation (REFS) engine with unprecedented supercomputing power and massive human patient multiomic and clinical data to develop in silico models of human disease biology that reveal the hidden circuitry.
Aitia’s Gemini Digital Twin platform reveals “hidden” 95% of genetic and molecular interactions that cause disease, and identifies a set of novel potential intervention points (e.g., novel causal drug targets) and biomarkers of patient response. These discoveries are validated in the bench and the clinic, and are being translated by our biopharma partners into a new generation of breakthrough precision drugs.
Aitia’s causal AI-based Gemini Digital Twin platform fuels differentiated and novel partnered programs across multiple diseases with high unmet medical need.
We are a world-class team of AI pioneers, R&D veterans, and biotech company builders backed by top-tier healthcare and strategic pharma investors and leaders working together toward our mission.
Our technology, data, and expertise in generating deep biological knowledge dovetails perfectly with our partner’s own data and pharmaceutical R&D expertise to accelerate the discovery and development of new therapies for multiple areas of unmet medical need, e.g., oncological, neuro-degenerative, immunological, and cardiometabolic diseases.
